20 studies found for:    PA-21
Show Display Options
Rank Status Study
1 Completed A Drug-Drug Interaction Study of Losartan and PA21
Condition: Drug Interaction Potentiation
Interventions: Drug: PA21 and Losartan with Food;   Drug: No PA21; Losartan with food;   Drug: PA21 with food and Losartan 2 hours later
2 Completed A Drug-Drug Interaction Study of Omeprazole and PA21
Condition: Healthy
Interventions: Drug: PA21 and Omeprazole with food;   Drug: No PA21; Omeprazole with food;   Drug: PA21 with food, Omeprazole 2hrs later
3 Completed A Drug-Drug Interaction Study of Furosemide and PA21
Condition: Healthy
Interventions: Drug: PA21 and Furosemide with food;   Drug: No PA21; Furosemide with food;   Drug: PA21 with food and Furosemide 2hrs later
4 Completed A Drug-Drug Interaction Study of Digoxin and PA21
Condition: Drug Interaction Potentiation
Interventions: Drug: PA21;   Drug: Digoxin
5 Completed A Drug-Drug Interaction Study of Warfarin and PA21
Condition: Drug Interaction Potentiation
Interventions: Drug: PA21;   Drug: Warfarin
6 Completed
Has Results
A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients
Condition: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron);   Drug: Sevelamer carbonate;   Drug: PA21-1 (1.25 g tablet containing 250 mg iron)
7 Completed
Has Results
Study of Phosphate Levels in Patients With Chronic Kidney Disease
Condition: Chronic Kidney Disease
Interventions: Drug: 1.25 g PA21 (250 mg iron);   Drug: 5.0 g PA21 (1,000 mg iron);   Drug: 7.5 g PA21 (1,500 mg iron);   Drug: 10.0 g PA21 (2,000 mg iron);   Drug: 12.5 g PA21 (2,500 mg iron);   Drug: Sevelamer hydrochloride
8 Completed
Has Results
A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients
Condition: Chronic Kidney Disease Requiring Chronic Dialysis
Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron);   Drug: Sevelamer carbonate
9 Completed PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Condition: Chronic Kidney Disease Requiring Hemodialysis
Interventions: Drug: PA21;   Drug: Placebo
10 Active, not recruiting A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Condition: Hemodialysis Patients With Hyperphosphatemia
Intervention: Drug: PA21
11 Active, not recruiting A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia
Conditions: Hemodialysis;   Hyperphosphatemia
Interventions: Drug: PA21;   Drug: Sevelamer hydrochloride
12 Active, not recruiting A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia
Conditions: Peritoneal Dialysis;   Hyperphosphatemia
Intervention: Drug: PA21
13 Active, not recruiting A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia
Conditions: Hemodialysis;   Hyperphosphatemia
Intervention: Drug: PA21
14 Recruiting PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma
Condition: Extranodal NK-T-Cell Lymphoma, Nasal and Nasal-Type
Interventions: Drug: pegaspargase;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Methotrexate;   Drug: Dexamethasone;   Drug: Thalidomide
15 Completed Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
Condition: Tuberculosis
Interventions: Drug: PA-824;   Drug: Efavirenz (EFV);   Drug: Lopinavir/Ritonavir (LPV/r);   Drug: Rifampin (RIF)
16 Completed Radiation Therapy for Heterotopic Ossification Prophylaxis Acutely After Elbow Trauma
Condition: Elbow Fracture
Intervention: Radiation: Radiation Therapy (XRT)
17 Recruiting Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel
Conditions: Diarrhea;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: cabazitaxel;   Drug: prednisone;   Drug: octreotide pamoate;   Other: questionnaire administration;   Drug: octreotide acetate
18 Withdrawn Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Nonmalignant Neoplasm
Interventions: Drug: cyclosporine;   Drug: mycophenolate mofetil;   Drug: pentostatin;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: protein analysis;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: laboratory biomarker analysis;   Other: reduced-intensity transplant conditioning procedure;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation (PBSC);   Radiation: total-body irradiation
19 Recruiting The Women In Steady Exercise Research (WISER) Survivor Trial
Condition: Lymphedema
Interventions: Behavioral: Exercise Intervention;   Behavioral: Weight Loss Intervention
20 Completed Effects of Nasal Septal Surgery on Sleep Quality, Daytime and Dream Anxiety
Condition: Nasal Septal Deviation
Interventions: Procedure: The active anterior rhinomanometry;   Behavioral: The Pittsburgh Sleep Quality Index (PSQI);   Behavioral: The Beck Anxiety Inventory (BAI);   Behavioral: The Van Dream Anxiety Scale (VDAS)

Indicates status has not been verified in more than two years